Cargando…

Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent

Enzyme replacement therapy (ERT) with recombinant human acid-α-glucosidase (rhGAA) is the only FDA approved therapy for Pompe disease. Without ERT, severely affected individuals (early onset) succumb to the disease within 2 years of life. A spectrum of disease severity and progression exists dependi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nayak, Sushrusha, Doerfler, Phillip A., Porvasnik, Stacy L., Cloutier, Denise D., Khanna, Richie, Valenzano, Ken J., Herzog, Roland W., Byrne, Barry J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045583/ https://www.ncbi.nlm.nih.gov/pubmed/24897114 http://dx.doi.org/10.1371/journal.pone.0098336

Ejemplares similares

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Targeted approaches to induce immune tolerance for Pompe disease therapy
por: Doerfler, Phillip A, et al.
Publicado: (2016)

The Release of a Soluble Glycosylated Protein from Glycogen by Recombinant Lysosomal α-Glucosidase (rhGAA) In Vitro and Its Presence in Serum In Vivo
por: Murray, Allen K.
Publicado: (2020)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

S3.1 Are there ERT defined guidelines for Pompe disease?
por: Toscano, Antonio, et al.
Publicado: (2011)

AAV Gene Therapy Utilizing Glycosylation-Independent Lysosomal Targeting Tagged GAA in the Hypoglossal Motor System of Pompe Mice
por: Doyle, Brendan M., et al.
Publicado: (2019)

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Effect of enzyme replacement therapy (ERT) added to Home Mechanical Ventilation (HMV) in Adult Pompe disease
por: Sayeed, Nadia, et al.
Publicado: (2015)

Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic
por: Fiumara, Agata, et al.
Publicado: (2023)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Broad variation in phenotypes for common GAA genotypes in Pompe disease
por: Niño, Monica Y., et al.
Publicado: (2021)

L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report
por: Rovelli, Valentina, et al.
Publicado: (2022)

Successful twin pregnancy in a 38-year-old woman with Pompe disease despite interruption of enzyme replacement therapy (ERT)
por: Tiling, N, et al.
Publicado: (2013)

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
por: Sun, Baodong, et al.
Publicado: (2014)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Enzyme Replacement Therapy (ERT) on Heart Function Changes the Outcome in Patients with Infantile-Onset Pompe Disease: A Familial History
por: Lecis, Marco, et al.
Publicado: (2023)

Identification a novel mononucleotide deletion mutation in GAA in pompe disease patients
por: Ebrahimi, Milad, et al.
Publicado: (2017)

A novel homozygous mutation at the GAA gene in Mexicans with early-onset Pompe disease
por: ESMER, CARMEN, et al.
Publicado: (2013)

The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease
por: Khanna, Richie, et al.
Publicado: (2012)

A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan
por: Fukuhara, Yasuyuki, et al.
Publicado: (2017)

GAA compound heterozygous mutations associated with autophagic impairment cause cerebral infarction in Pompe disease
por: Jia, Xiaodong, et al.
Publicado: (2020)

Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease
por: Gal, Aniko, et al.
Publicado: (2021)

Muscle‐directed gene therapy corrects Pompe disease and uncovers species‐specific GAA immunogenicity
por: Eggers, Michelle, et al.
Publicado: (2021)

GAA Deficiency in Pompe Disease Is Alleviated by Exon Inclusion in iPSC-Derived Skeletal Muscle Cells
por: van der Wal, Erik, et al.
Publicado: (2017)

Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis
por: in ’t Groen, Stijn L.M., et al.
Publicado: (2020)

Genotypephenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants
por: Hernndez-Arvalo, Paula, et al.
Publicado: (2021)

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
por: Banugaria, Suhrad G., et al.
Publicado: (2013)

A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations
por: Herzog, Andreas, et al.
Publicado: (2012)

Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice
por: Falk, Darin J, et al.
Publicado: (2015)

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
por: Kazi, Zoheb B., et al.
Publicado: (2018)

(13)C/(31)P MRS Metabolic Biomarkers of Disease Progression and Response to AAV Delivery of hGAA in a Mouse Model of Pompe Disease
por: Baligand, Celine, et al.
Publicado: (2017)

Novel Mutation in the Feline GAA Gene in a Cat with Glycogen Storage Disease Type II (Pompe Disease)
por: Rakib, Tofazzal Md, et al.
Publicado: (2023)

GAA variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing
por: Malekkou, Anna, et al.
Publicado: (2023)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

Hackertámadás érte a svájci részecskegyorsító rendszerét
Publicado: (2008)

Rekord energiaszintet ért el az LHC
Publicado: (2009)

ERT, HRT, Raloxifine, Calcitonin, or Bisphosphonates for Osteoporosis
por: Curtiss, Frederic R.
Publicado: (2003)

Analysis of barley mutants ert-c.1 and ert-d.7 reveals two loci with additive effect on plant architecture
por: Lu, Qiongxian, et al.
Publicado: (2021)

Warning regarding hematological toxicity of tamoxifen activated CreERT2 in young Rosa26CreERT2 mice
por: Rossi, Martina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_afo4p45dnrnppc5jpr3noked16